太阳能居住建筑市场化推广研究.docx

Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）

Revenues:收入

Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,
Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale of
research reagents.2011年12月31日止年度，2010年和2009年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。

Collaboration revenue:合作收入

Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from Salix, which includes
$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and
$15,232 as reimbursement of our expenses, including $2,172 of manufacturing supplies, in accordance with the License Agreement. As ofDecember 31, 2011, $204 and $162 are recorded in deferred revenue – current and long-term, respectively.

Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383, respectively, of
revenue from Wyeth, as reimbursement of our expenses under the 2009 Transition Agreement.

During the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,
consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimbursement of our development expenses, and (iii) $1,383 and $10,000, respectively, as reimbursement of ourexpenses under the 2009 Transition Agreement.

Ono Collaboration. During the years ended December 31, 2011 and 2010, we recognized $43 and $30, respectively, of
reimbursement revenue for activities requested by Ono.
我们认识到，二零一一年及二零一零年十二月三十一日止期间，$43和$30，分别，小野合作补偿收入所要求的小野的活动。
During the years ended December 31, 2010 and 2009, we recognized $30 and $53, respectively, of reimbursement revenue for
activities requested by Ono and in 2009 recognized the $15,000 upfront payment as revenue, due to satisfying our performance obligations2010年和2009年截至12月31.期间，我们认识到在30和53美元，美元，分别报销的收入由于要满足我们的性能义务。活动要求小野并于2009年确认为收入1.5万美元的首期付款。

Royalty income. We began earning royalties from net sales by Wyeth of subcutaneous RELISTOR in June 2008. Under our 2009
Transition Agreement, Wyeth continued to distribute RELISTOR in the U.S. until April 1, 2011, in Europe until October 1, 2011, and in
Australia until December 1, 2011, at which times Salix assumed those responsibilities. Royalties due to us during 2011 are attributable only toSalix net sales in those territories from the date in which Salix assumed responsibility, the basis for 2011 royalty income. From April 1, 2011 toDecember 31, 2011, we earned royalty income of $3,046 based on net sales of RELISTOR reported by Salix or its sublicensees.

During the years ended December 31, 2010 and 2009, royalties of $1,826 and $1,853, respectively, were owed to us based on the netsales of RELISTOR reported by Wyeth and we recognized royalty revenue of $1,826 and $2,372, respectively. During the fourth quarter of2010, no royalties were payable to us.
在十二月三十一日止，2010年和2009年，分别1826美元1853美元，特许权使用费，被拖欠的基础上的纯销售的RELISTOR报告由惠氏公司和我们确认使用费收入，分别，1826美元2372美元。在第四季度of2010，没有特许权使用费支付给我们。
Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）

Revenues:收入

Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,
Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale of
research reagents.2011年12月31日止年度，2010年和2009年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。

Collaboration revenue:合作收入

Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from Salix, which includes
$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and
$15,232 as reimbursement of our expenses, including $2,172 of manufacturing supplies, in accordance with the License Agreement. As ofDecember 31, 2011, $204 and $162 are recorded in deferred revenue – current and long-term, respectively.

Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383, respectively, of
revenue from Wyeth, as reimbursement of our expenses under the 2009 Transition Agreement.

During the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,
consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimbursement of our development expenses, and (iii) 1,383 and $10,000, respectively, as reimbursement of ourexpenses under the 2009 Transition Agreement.

Ono Collaboration. During the years ended December 31, 2011 and 2010, we recognized $43 and $30, respectively, of
reimbursement revenue for activities requested by Ono.
我们认识到，二零一一年及二零一零年十二月三十一日止期间，$43和$30，分别，小野合作补偿收入所要求的小野的活动。
During the years ended December 31, 2010 and 2009, we recognized $30 and $53, respectively, of reimbursement revenue for
activities requested by Ono and in 2009 recognized the $15,000 upfront payment as revenue, due to satisfying our performance obligations2010年和2009年截至12月31.期间，我们认识到在30和53美元，美元，分别报销的收入由于要满足我们的性能义务。活动要求小野并于2009年确认为收入1.5万美元的首期付款。

Royalty income. We began earning royalties from net sales by Wyeth of subcutaneous RELISTOR in June 2008. Under our 2009
Transition Agreement, Wyeth continued to distribute RELISTOR in the U.S. until April 1, 2011, in Europe until October 1, 2011, and in
Australia until December 1, 2011, at which times Salix assumed those responsibilities. Royalties due to us during 2011 are attributable only toSalix net sales in those territories from the date in which Salix assumed responsibility, the basis for 2011 royalty income. From April 1, 2011 toDecember 31, 2011, we earned royalty income of $3,046 based on net sales of RELISTOR reported by Salix or its sublicensees.

During the years ended December 31, 2010 and 2009, royalties of $1,826 and $1,853, respectively, were owed to us based on the netsales of RELISTOR reported by Wyeth and we recognized royalty revenue of $1,826 and $2,372, respectively. During the fourth quarter of2010, no royalties were payable to us.
在十二月三十一日止，2010年和2009年，分别1826美元1853美元，特许权使用费，被拖欠的基础上的纯销售的RELISTOR报告由惠氏公司和我们确认使用费收入，分别，1826美元2372美元。在第四季度of2010，没有特许权使用费支付给我们。

Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）

Revenues:收入

Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,
Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale of
research reagents.2011年12月31日止年度，2010年和2009年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。

Collaboration revenue:合作收入

Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from Salix, which includes
$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and
$15,232 as reimbursement of our expenses, including $2172 of manufacturing supplies, in accordance with the License Agreement. As ofDecember 31, 2011, $204 and $162 are recorded in deferred revenue – current and long-term, respectively.

Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383 respectively, of
revenue from Wyeth, as reimbursement of our expenses under the 2009 Transition Agreement.

During the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,
consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimbursement of our development expenses, and (iii) $1,383 and $10,000, respectively, as reimbursement of ourexpenses under the 2009 Transition Agreement.

Ono Collaboration. During the years ended December 31, 2011 and 2010, we recognized $43 and $30, respectively, of
reimbursement revenue for activities requested by Ono.
我们认识到，二零一一年及二零一零年十二月三十一日止期间，$43和$30，分别，小野合作补偿收入所要求的小野的活动。
During the years ended December 31, 2010 and 2009, we recognized $30 and $53 respectively, of reimbursement revenue for
activities requested by Ono and in 2009 recognized the $15,000 upfront payment as revenue, due to satisfying our performance obligations2010年和2009年截至12月31.期间，我们认识到在30和53美元，美元，分别报销的收入由于要满足我们的性能义务。活动要求小野并于2009年确认为收入1.5万美元的首期付款。

Royalty income. We began earning royalties from net sales by Wyeth of subcutaneous RELISTOR in June 2008. Under our 2009
Transition Agreement, Wyeth continued to distribute RELISTOR in the U.S. until April 1, 2011, in Europe until October 1, 2011, and in
Australia until December 1, 2011, at which times Salix assumed those responsibilities. Royalties due to us during 2011 are attributable only toSalix net sales in those territories from the date in which Salix assumed responsibility, the basis for 2011 royalty income. From April 1, 2011 toDecember 31, 2011, we earned royalty income of $3,046 based on net sales of RELISTOR reported by Salix or its sublicensees.

During the years ended December 31, 2010 and 2009, royalties of $1,826 and $1,853, respectively, were owed to us based on the netsales of RELISTOR reported by Wyeth and we recognized royalty revenue of $1,826 and $2,372, respectively. During the fourth quarter of2010, no royalties were payable to us.
在十二月三十一日止，2010年和2009年，分别1826美元1853美元，特许权使用费，被拖欠的基础上的纯销售的RELISTOR报告由惠氏公司和我们确认使用费收入，分别，1826美元2372美元。在第四季度of2010，没有特许权使用费支付给我们。

Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）

Revenues:收入

Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,
Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale of
research reagents.2011年12月31日止年度，2010年和2009年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。

Collaboration revenue:合作收入

Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from Salix, which includes
$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and
$15,232 as reimbursement of our expenses, including $2,172 of manufacturing supplies, in accordance with the License Agreement. As ofDecember 31, 2011, $204 and $162 are recorded in deferred revenue – current and long-term, respectively.

Wyeth Collaboration. During the years ended December 31, 2011 and 2010, we recognized $1,630 and $1,383, respectively, of
revenue from Wyeth, as reimbursement of our expenses under the 2009 Transition Agreement.

During the years ended December 31, 2010 and 2009, we recognized $1,383 and $29,298, respectively, of revenue from Wyeth,
consisting of (i) $0 and $14,562, respectively, of the $60,000 upfront payment we received upon entering into our 2005 collaboration, (ii) $0and $4,736, respectively, as reimbursement of our development expenses, and (iii) $1,383 and $10,000, respectively, as reimbursement of ourexpenses under the 2009 Transition Agreement.

Ono Collaboration. During the years ended December 31, 2011 and 2010, we recognized $43 and $30, respectively, of
reimbursement revenue for activities requested by Ono.
我们认识到，二零一一年及二零一零年十二月三十一日止期间，$43和$30，分别，小野合作补偿收入所要求的小野的活动。
During the years ended December 31, 2010 and 2009, we recognized $30 and $53, respectively, of reimbursement revenue for
activities requested by Ono and in 2009 recognized the $15,000 upfront payment as revenue, due to satisfying our performance obligations2010年和2009年截至12月31.期间，我们认识到在30和53美元，美元，分别报销的收入由于要满足我们的性能义务。活动要求小野并于2009年确认为收入1.5万美元的首期付款。

Royalty income. We began earning royalties from net sales by Wyeth of subcutaneous RELISTOR in June 2008. Under our 2009
Transition Agreement, Wyeth continued to distribute RELISTOR in the U.S. until April 1, 2011, in Europe until October 1, 2011, and in
Australia until December 1, 2011, at which times Salix assumed those responsibilities. Royalties due to us during 2011 are attributable only toSalix net sales in those territories from the date in which Salix assumed responsibility, the basis for 2011 royalty income. From April 1, 2011 toDecember 31, 2011, we earned royalty income of $3,046 based on net sales of RELISTOR reported by Salix or its sublicensees.

During the years ended December 31, 2010 and 2009, royalties of $1,826 and $1,853, respectively, were owed to us based on the netsales of RELISTOR reported by Wyeth and we recognized royalty revenue of $1,826 and $2,372, respectively. During the fourth quarter of2010, no royalties were payable to us.
在十二月三十一日止，2010年和2009年，分别1826美元1853美元，特许权使用费，被拖欠的基础上的纯销售的RELISTOR报告由惠氏公司和我们确认使用费收入，分别，1826美元2372美元。在第四季度of2010，没有特许权使用费支付给我们。

Results of Operations (amounts in thousands unless otherwise noted)经营业绩（单位：除非另有说明）

Revenues:收入

Our sources of revenue during the years ended December 31, 2011, 2010 and 2009, included our License Agreement with Salix,
Transition Agreement with Wyeth, our License Agreement with Ono, our research grants from the NIH and, to a small extent, our sale of
research reagents.2011年12月31日止年度，2010年和2009年，我们的收入来源，包括我们与柳许可协议，和惠氏的过渡协议，我们与小野的许可协议，我们的研究资助，由美国国立卫生研究院，并在小范围内，我们销售研究试剂。

Collaboration revenue:合作收入

Salix Collaboration. During the year ended December 31, 2011, we recognized $75,091 of revenue from Salix, which includes
$59,634 from the $60,000 upfront cash payment under the License Agreement, $225 in respect of Salix ex-U.S. sublicensee revenue and
$15,232 as reimbursement of our expenses, including $2,172 of manufa